熱門資訊> 正文

Abivax报告财年业绩

2026-03-24 04:16

阿斯利康(AZN) 0
禮來製藥(LLY) 0

Abivax press release (ABVX): FY
The Company had cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025, providing a projected cash runway into Q4 2027 based on current operating assumptions.
Research and development (“R&D”) expenses increased by €31.2 million to €177.8 million (70.9% of operating expenses) in 2025 compared to €146.5 million (79.0% of operating expenses) in 2024.

More on Abivax

Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax pares gain after denying AstraZeneca speculation
Abivax CEO responds to Lilly acquisition rumors
Seeking Alpha’s Quant Rating on Abivax

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。